A Bold Investment Strategy Focused on Building on Innovation
3B Future Health Fund supports US and European-based private early-stage, innovative companies in areas of high unmet patient needs.
Guided by our core values, inspired by the needs of patients and with a passion for science and oncology, we leverage our expertise and network to bring life-changing treatments to patients.
We strive to be the preferred partner to select investors and portfolio companies, motivated by a sense of purpose, excellent execution, personal involvement and premium performance.
Looking for companies sharing our core values of QUALITY, INTEGRITY & RESPECT, and a strong passion for bringing new life-changing treatments to patients.
We focus on start-up companies based in Europe, the US and Israel. We support companies with potential first-in-class assets, revolutionary insights, experienced management teams and a strong investor syndicate. We typically make our initial investment in companies raising Series A rounds, but in some cases even earlier.
Team with proven track-record founded on robust due diligence and efficient work processes. Invest only in First Class Science & Technology. 3B FUTURE Health Fund has made 12 investments with one highly profitable exit to date.
10-year fund – Investment in target companies to be held for five to eight years, or fewer if value inflection points are reached which could permit earlier exits.
Focus / Geography
Focus / Geography
100% healthcare, early stage and clinical development stage.
Therapeutic areas with strong unmet patient needs; priority on US and European-based startups focusing mainly on oncology and rare diseases, leveraging the expertise of the team.
Opportunistic investments, made on a case-by-case basis.
Fund comprised of 10-15 companies, up to $12 million investment in each and Board position desirable.
We reserve capital for follow-on rounds.
Our team is building a diversified portfolio designed to balance the risks and optimise potential returns by investing in companies at early and mid-stages of development, with different levels of complexity in science and technology, drug modality agnostic and based across different geographies.View our full portfolio
IDENTIFYING SCIENCE AND TECHNOLOGY WITH THE POTENTIAL TO TRANSFORM PATIENTS’ LIVES
40+ years of building successful
24 February 2021NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
21 September 2020Novellus Closes $57M Series C Financing
10 September 2020Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
21 July 2020Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
14 July 20203B Future Health Fund Announces New Investment in iOnctura
8 June 2020QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test
31 January 2020Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
30 January 2020The GreenBone bone substitute achieves CE certification
15 July 2019Helsinn Investment Fund Announces First Exit
19 March 2019Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced
19 February 2019Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
23 January 2019QuantuMDx & St George’s begin field study: cervical cancer screening test
Get in Touch
For further information, please contact us using the form below.
Someone from the team will be in contact in due course.
Thank you for your form submission, we will get in contact with you shortly.